Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma

a multicenter prospective phase II study (JSCT-NHL04)

Tohru Murayama, Takahiro Fukuda, Hirokazu Okumura, Kazutaka Sunami, Aiko Sawazaki, Yoshinobu Maeda, Hisashi Tsurumi, Naokuni Uike, Tomonori Hidaka, Yoshifusa Takatsuka, Tetsuya Eto, Hiroyuki Tsuda, Tomoaki Fujisaki, Toshihiro Miyamoto, Naoko Tsuneyoshi, Satoshi Iyama, Koji Nagafuji, Mine Harada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

To evaluate the efficacy and feasibility of upfront high-dose chemotherapy (HDCT) and rituximab (R) followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) in patients with newly diagnosed high-intermediate(HI)-, and high(H)-risk diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter prospective phase II trial. In 15–60-year-old patients with H- or HI-risk DLBCL, after three courses of (R-)CHOP14, high-dose etoposide was given prior to peripheral blood stem cell harvesting. After an additional three courses of (R-)CHOP14, auto-PBSCT was performed following HDCT. The primary endpoint of the study is progression-free survival (PFS) at 2 years after registration in eligible patients. The expected PFS and the threshold PFS were estimated to be 70 and 50 %, respectively. Among 40 eligible patients registered, 30 patients completed treatment. With a median observation period in surviving eligible patients of 63 months, the 2- and 4-year PFS after registration were 79.9 and 72.0 %, respectively. The 2- and 4-year overall survival (OS) were 92.5 and 84.6 %, respectively. In 30 patients who completed treatment, the 4-year PFS and OS after auto-PBSCT were 79.2 and 85.9 %, respectively. In conclusion, the results of our study suggest that upfront HDCT and auto-PBSCT combined with rituximab is highly effective as an initial treatment for HI-, and H-risk DLBCL.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalInternational Journal of Hematology
DOIs
Publication statusAccepted/In press - Mar 21 2016

Fingerprint

Peripheral Blood Stem Cell Transplantation
Lymphoma, Large B-Cell, Diffuse
Disease-Free Survival
Drug Therapy
Survival
Etoposide
Rituximab
Therapeutics
Observation

Keywords

  • Autologous peripheral blood stem cell transplantation
  • CHOP14
  • Diffuse large B-cell lymphoma
  • High-dose chemotherapy
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma : a multicenter prospective phase II study (JSCT-NHL04). / Murayama, Tohru; Fukuda, Takahiro; Okumura, Hirokazu; Sunami, Kazutaka; Sawazaki, Aiko; Maeda, Yoshinobu; Tsurumi, Hisashi; Uike, Naokuni; Hidaka, Tomonori; Takatsuka, Yoshifusa; Eto, Tetsuya; Tsuda, Hiroyuki; Fujisaki, Tomoaki; Miyamoto, Toshihiro; Tsuneyoshi, Naoko; Iyama, Satoshi; Nagafuji, Koji; Harada, Mine.

In: International Journal of Hematology, 21.03.2016, p. 1-10.

Research output: Contribution to journalArticle

Murayama, Tohru ; Fukuda, Takahiro ; Okumura, Hirokazu ; Sunami, Kazutaka ; Sawazaki, Aiko ; Maeda, Yoshinobu ; Tsurumi, Hisashi ; Uike, Naokuni ; Hidaka, Tomonori ; Takatsuka, Yoshifusa ; Eto, Tetsuya ; Tsuda, Hiroyuki ; Fujisaki, Tomoaki ; Miyamoto, Toshihiro ; Tsuneyoshi, Naoko ; Iyama, Satoshi ; Nagafuji, Koji ; Harada, Mine. / Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma : a multicenter prospective phase II study (JSCT-NHL04). In: International Journal of Hematology. 2016 ; pp. 1-10.
@article{7e7348e060a9482eb22ed8c7c69d3a58,
title = "Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04)",
abstract = "To evaluate the efficacy and feasibility of upfront high-dose chemotherapy (HDCT) and rituximab (R) followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) in patients with newly diagnosed high-intermediate(HI)-, and high(H)-risk diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter prospective phase II trial. In 15–60-year-old patients with H- or HI-risk DLBCL, after three courses of (R-)CHOP14, high-dose etoposide was given prior to peripheral blood stem cell harvesting. After an additional three courses of (R-)CHOP14, auto-PBSCT was performed following HDCT. The primary endpoint of the study is progression-free survival (PFS) at 2 years after registration in eligible patients. The expected PFS and the threshold PFS were estimated to be 70 and 50 {\%}, respectively. Among 40 eligible patients registered, 30 patients completed treatment. With a median observation period in surviving eligible patients of 63 months, the 2- and 4-year PFS after registration were 79.9 and 72.0 {\%}, respectively. The 2- and 4-year overall survival (OS) were 92.5 and 84.6 {\%}, respectively. In 30 patients who completed treatment, the 4-year PFS and OS after auto-PBSCT were 79.2 and 85.9 {\%}, respectively. In conclusion, the results of our study suggest that upfront HDCT and auto-PBSCT combined with rituximab is highly effective as an initial treatment for HI-, and H-risk DLBCL.",
keywords = "Autologous peripheral blood stem cell transplantation, CHOP14, Diffuse large B-cell lymphoma, High-dose chemotherapy, Rituximab",
author = "Tohru Murayama and Takahiro Fukuda and Hirokazu Okumura and Kazutaka Sunami and Aiko Sawazaki and Yoshinobu Maeda and Hisashi Tsurumi and Naokuni Uike and Tomonori Hidaka and Yoshifusa Takatsuka and Tetsuya Eto and Hiroyuki Tsuda and Tomoaki Fujisaki and Toshihiro Miyamoto and Naoko Tsuneyoshi and Satoshi Iyama and Koji Nagafuji and Mine Harada",
year = "2016",
month = "3",
day = "21",
doi = "10.1007/s12185-016-1976-4",
language = "English",
pages = "1--10",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma

T2 - a multicenter prospective phase II study (JSCT-NHL04)

AU - Murayama, Tohru

AU - Fukuda, Takahiro

AU - Okumura, Hirokazu

AU - Sunami, Kazutaka

AU - Sawazaki, Aiko

AU - Maeda, Yoshinobu

AU - Tsurumi, Hisashi

AU - Uike, Naokuni

AU - Hidaka, Tomonori

AU - Takatsuka, Yoshifusa

AU - Eto, Tetsuya

AU - Tsuda, Hiroyuki

AU - Fujisaki, Tomoaki

AU - Miyamoto, Toshihiro

AU - Tsuneyoshi, Naoko

AU - Iyama, Satoshi

AU - Nagafuji, Koji

AU - Harada, Mine

PY - 2016/3/21

Y1 - 2016/3/21

N2 - To evaluate the efficacy and feasibility of upfront high-dose chemotherapy (HDCT) and rituximab (R) followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) in patients with newly diagnosed high-intermediate(HI)-, and high(H)-risk diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter prospective phase II trial. In 15–60-year-old patients with H- or HI-risk DLBCL, after three courses of (R-)CHOP14, high-dose etoposide was given prior to peripheral blood stem cell harvesting. After an additional three courses of (R-)CHOP14, auto-PBSCT was performed following HDCT. The primary endpoint of the study is progression-free survival (PFS) at 2 years after registration in eligible patients. The expected PFS and the threshold PFS were estimated to be 70 and 50 %, respectively. Among 40 eligible patients registered, 30 patients completed treatment. With a median observation period in surviving eligible patients of 63 months, the 2- and 4-year PFS after registration were 79.9 and 72.0 %, respectively. The 2- and 4-year overall survival (OS) were 92.5 and 84.6 %, respectively. In 30 patients who completed treatment, the 4-year PFS and OS after auto-PBSCT were 79.2 and 85.9 %, respectively. In conclusion, the results of our study suggest that upfront HDCT and auto-PBSCT combined with rituximab is highly effective as an initial treatment for HI-, and H-risk DLBCL.

AB - To evaluate the efficacy and feasibility of upfront high-dose chemotherapy (HDCT) and rituximab (R) followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) in patients with newly diagnosed high-intermediate(HI)-, and high(H)-risk diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter prospective phase II trial. In 15–60-year-old patients with H- or HI-risk DLBCL, after three courses of (R-)CHOP14, high-dose etoposide was given prior to peripheral blood stem cell harvesting. After an additional three courses of (R-)CHOP14, auto-PBSCT was performed following HDCT. The primary endpoint of the study is progression-free survival (PFS) at 2 years after registration in eligible patients. The expected PFS and the threshold PFS were estimated to be 70 and 50 %, respectively. Among 40 eligible patients registered, 30 patients completed treatment. With a median observation period in surviving eligible patients of 63 months, the 2- and 4-year PFS after registration were 79.9 and 72.0 %, respectively. The 2- and 4-year overall survival (OS) were 92.5 and 84.6 %, respectively. In 30 patients who completed treatment, the 4-year PFS and OS after auto-PBSCT were 79.2 and 85.9 %, respectively. In conclusion, the results of our study suggest that upfront HDCT and auto-PBSCT combined with rituximab is highly effective as an initial treatment for HI-, and H-risk DLBCL.

KW - Autologous peripheral blood stem cell transplantation

KW - CHOP14

KW - Diffuse large B-cell lymphoma

KW - High-dose chemotherapy

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84963766464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963766464&partnerID=8YFLogxK

U2 - 10.1007/s12185-016-1976-4

DO - 10.1007/s12185-016-1976-4

M3 - Article

SP - 1

EP - 10

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

ER -